On July 12, it was announced by the National Growth Fund
that PharmaNL has met the conditions to convert the conditional award of €78.8
million to a final grant. “From PharmaNL we are very pleased with this
news. Together with the stakeholders, we can now set to work to realize the
ambitions of PharmaNL,” said Brigitte Drees, Director of Pivot Park.
PharmaNL is a national public-private consortium consisting
of Leiden University Medical Center, Leiden University, Campus Groningen,
LifeCooperative, Pivot Park, and in close cooperation with FAST – Platform to
Future Affordable Sustainable Therapies. PharmaNL will start with an eighty
million subsidy from the National Growth Fund to invest in research facilities
and human capital.
View the official announcement from the central government